Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A dose-ranging Phase 2b trial of ORKA-001 in moderate-to-severe PsO patients

Next Previous
Trial Profile

A dose-ranging Phase 2b trial of ORKA-001 in moderate-to-severe PsO patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ORKA 001 (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms EVERLAST-B

Most Recent Events

  • 04 Nov 2025 New trial record
  • 17 Sep 2025 According to an Oruka Therapeutics media release, company expects that its cash will fund its operations for at least one year following the ORKA-002 Phase 2 and ORKA-001 EVERLAST-B Phase 2b data readouts in 2027.
  • 17 Sep 2025 According to an Oruka Therapeutics media release, company expects to initiate a dose-ranging Phase 2b trial of ORKA-001 in moderate-to-severe PsO patients, EVERLAST-B, in 1H 2026. To expedite development, EVERLAST-B dosing is projected to begin enrolling before the completion of EVERLAST-A.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top